FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss

FDA
The FDA has asked that Summit Therapeutics conduct a new adequate and well-controlled global clinical trial if it ever wants to pursue the same indication for ivonescimab in previously treated, EGFR-mutated NSCLC. (Photo by Sarah Silbiger/Getty Images)

The FDA’s rejection of Summit Therapeutics’ closely watched PD-1xVEGF bispecific ivonescimab extends beyond its previously reported failure to show a statistically significant overall survival benefit.

In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged concerns over the geographic makeup of Summit’s supporting trial, HARMONi, noting that 93% of the progression-free survival events occurred in patients enrolled in China.

Because of that imbalance, regulators said they could not determine whether the study’s positive PFS readout can be applied to U.S. patients. 

The agency also recounted its concerns flagged repeatedly in 2023 and 2025 regarding the enrollment approach for the phase 3 trial. 

For HARMONi, Summit rolled over patients who had previously received a third-generation EGFR tyrosine kinase inhibitor from partner Akeso’s existing HARMONi-A trial, which was conducted solely in China. As a result, the global trial didn’t start enrolling patients from the U.S. and Europe until nearly a year and a half after the China study’s initiation.

Summit’s attempt at accelerating a global readout backfired. When HARMONi reported its final overall survival analysis, which missed statistical significance, the follow-up in the Western population was immature, as Chinese patients contributed to the bulk of events. 

To make up for the flop, Summit conducted additional follow-up of the Western population and did show some promising signs indicating consistency in overall survival across regions.

However, in its CRL, the FDA determined that the submitted post-hoc OS analyses are “exploratory only,” and are “further limited by differential data cutoff (DCO) dates across regions.”

What’s more, the FDA argued that the “modest improvement” in median PFS—from 4.4 months for chemotherapy to 6.8 months with ivonescimab plus chemo—“does not outweigh the risks of ivonescimab,” given its added toxicities.

In conclusion, the FDA has asked that Summit conduct a new adequate and well-controlled global clinical trial if it ever wants to pursue the same indication of previously treated, EGFR-mutated NSCLC.

Following Summit’s disclosure of the CRL over the weekend, the company’s stock price dropped 16.4% during Monday’s trading and again declined by about 10% Tuesday by publication time.

In skipping its third-quarter investor call in early November, Summit said it would hold a call following the FDA decision, but it has not followed through on that promise. Fierce has reached out to the company for comments.

Summit is contemplating a resubmission, Citi analysts said in a Nov. 16 note after speaking with the company’s management team. 

In contrast, Summit’s partner, Akeso, held an investor call on Sunday, during which CEO Michelle Xia, Ph.D., expressed disappointment in the FDA’s decision. 

“To be honest, in the 14 years since Akeso was founded, this is the most disappointing moment for me personally,” Xia said. 

Consistent with Summit’s previous communication, Xia said Akeso and Summit convinced the FDA to agree to the sequential enrollment design that makes HARMONi essentially a continuation of the Chinese HARMONi-A trial. At the same time, the FDA stated from the beginning that the global study needed to achieve statistical significance in OS, Xia recalled.

“It really boils down to that simple conclusion: without statistically significant OS, the submission was deemed insufficient for approval,” she said.

The chief executive added that the clinical trial sites and Akeso’s Guangzhou manufacturing facility had all passed the FDA’s inspections. 

Xia also highlighted that the FDA recognized ivonescimab’s safety profile, citing similar treatment discontinuations and treatment-related deaths in the ivonescimab arm and the chemo group. 

“Adding ivonescimab on top of single-agent chemotherapy and achieving such a great safety profile is hugely encouraging to overseas investigators,” she said.

In conclusion, Xia suggested that the FDA rejection should be viewed as an isolated case involving a relatively small indication, and that broader enthusiasm around the PD-1xVEGF class remains strong. 

Analysts agree, too. Attention on ivonescimab is turning to the upcoming readout of HARMONi-3 in first-line NSCLC, with a final PFS analysis in the squamous cohort expected this year. 

“HARMONi-3’s final progression-free survival (PFS) analysis in 1L squamous (SQ) NSCLC remains the critical catalyst for the stock,” Leerink Partners analysts wrote in a Nov. 15 note.